Group 1 - The company, Junshi Biosciences (01877), has received a registration notice for its technology innovation bonds from the China Interbank Market Dealers Association [1] - The registered amount for the medium-term notes is set at RMB 2 billion, with a validity period of two years from the date of the notice [1] - Shanghai Bank Co., Ltd. will act as the lead underwriter for this bond issuance [1]

Core Viewpoint - The company has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds, allowing it to issue bonds worth up to 2 billion RMB [1] Group 1: Bond Registration Details - The registered bond type is medium-term notes with a total registration amount of 2 billion RMB [1] - The registration validity period is effective for 2 years from the date of the notice [1] - Shanghai Bank Co., Ltd. is the lead underwriter for the bond issuance [1] Group 2: Issuance Strategy - The company can issue the technology innovation bonds in tranches during the registration validity period [1] - The timing of the bond issuance will depend on the company's funding needs and market conditions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於收到中國銀行間市場交易商協會<接受註冊 通知書>的公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年12月28日 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）2024 年年度股东 大会审议通过了《关于发行境内外债务融资工具的一般性授权的议案》， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* （股份代號：1877） 獲中國銀行間市場交易商協會接受註冊中期票據 本公告由上海君實生物醫藥科技股份有限公司（「本公司」）自願作出。請亦參見本 公司於2025年12月28日刊發的海外監管公告。 近日，本公司收到中國銀行間市場交易商協會（「交易商協會」）印發的《接受註冊 通知書》（中市協注[2025]MTN1249號）（「通知書」），交易商協會決定接受本公司 科技創新債券註冊。現就有關事項公告如下： 本公司將按照有關法律法規的要求及本公司股東會的授權，在規定的有效期內， 根據資金需求和市場情況擇機實施本次科技創新債券發行事宜，並按照相關規定 及時進行披露。 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 1 一、本公司本次註冊基礎品種為中期票據，註冊金額為人民幣20億元，註冊額度 自本通知書落款之日 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-076 上海君实生物医药科技股份有限公司 关于收到中国银行间市场交易商协会 《接受注册通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）2024 年年度股东 大会审议通过了《关于发行境内外债务融资工具的一般性授权的议案》，同意公 司注册发行不超过人民币 25 亿元或等值外币的境内外债务融资工具，并一般及 无条件授权董事会并由董事会转授权董事长及其授权人士根据公司不时的需要 以及市场条件全权决定及办理债务融资工具发行的全部事宜，以及由董事会进一 步授权董事长及其授权人士根据公司需要以及其它市场条件等具体执行债务融 资工具发行事宜，详见公司在 2025 年 6 月 21 日于上海证券交易所网站 （www.sse.com.cn）等披露的《上海君实生物医药科技股份有限公司 2024 年年 度股东大会决议公告》（公告编号：临 2025-035）。 近日，公司收到中国银行间市场交易商协会（以下简称"交易 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2] Group 1: Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020, specializing in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7] - The company's main revenue sources include 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] - As of September 30, 2023, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8] Group 2: Product Development and Pipeline - The company has developed a strong product pipeline, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2] - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple countries including the US, EU, and Australia [2] - Junshi Biosciences is also developing Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in progress [2] Group 3: Collaborations and Innovations - On October 27, 2023, Junshi Biosciences announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3] - The company’s subsidiary, JunTuo Biotech, is involved in the preclinical development of vaccines for monkeypox and Zika virus [3] Group 4: Market Performance - On December 24, 2023, Junshi Biosciences' stock fell by 0.83%, with a trading volume of 277 million yuan and a market capitalization of 35.534 billion yuan [1] - The stock has experienced a net outflow of 32.026 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]

人民财讯12月24日电，企查查APP显示，近日，宁波甬元兴仑君金创业投资合伙企业(有限合伙)成立， 出资额5亿元，经营范围包含：创业投资(限投资未上市企业)。企查查股权穿透显示，该企业由君实生 物、宁波市甬元投资基金有限公司等共同出资。 ...

中国经济网北京12月19日讯 君实生物（688180.SH）昨日晚间披露《关于持股5%以上股东减持股 份计划的公告》。 根据公告，上海檀英投资合伙企业（有限合伙）（以下简称"上海檀英"）计划通过大宗交易的方式 减持其持有的公司股份数量不超过20,533,797股，减持比例不超过公司总股本的2%。减持期间为2026年 1月13日至2026年4月10日。 截至公告披露日，上海檀英持有君实生物股份59,459,326股，股份性质为A股，占公司总股本的 5.7914%。上述股份为公司首次公开发行股票并在上海证券交易所科创板上市前取得的股份，且已于 2021年7月15日起解除限售并上市流通。 上海檀英为公司第三大股东。上述减持主体存在一致行动人：上海檀英的执行事务合伙人为上海正 心谷投资管理有限公司，实际控制人为林利军，上海檀英持有公司股份的性质为A股。Loyal Valley Capital Advantage Fund II LP及LVC Renaissance Fund LP均为林利军实际控制的合伙企业，其持有公司股 份的性质为H股。上海檀英及其一致行动人合计持有公司股份75,217,999股，占公司总股本的7. ...

Market Overview - The US CPI annual rate decline has led to a rise in US stocks, boosting risk market sentiment [1] - The Hang Seng Index opened higher and closed up 0.75%, with the Hang Seng China Enterprises Index and Hang Seng Tech Index rising by 0.68% and 1.12% respectively [1][2] Sector Performance - Major technology stocks saw collective gains, with Tencent up 1.49%, Kuaishou up 1.45%, and Meituan up 1.28% [4] - Pharmaceutical stocks were active, with WuXi AppTec and other related stocks rising [2] - Gaming stocks continued to rise, with MGM China leading with a 6.6% increase [2][5] - AI-driven demand boosted optical fiber and cable stocks, with Yangtze Optical Fiber rising 12% [2] - Automotive, wind power, education, photovoltaic, insurance, and Apple-related stocks also experienced gains [2] Notable Stock Movements - Xpeng Motors rose 7.65%, Horizon Robotics up 7.04%, and Li Auto up 3.81% [4][10] - Electronic cigarette stocks saw significant increases, with China Tobacco Hong Kong up 6.68% [5] - Chinese brokerage stocks rose, with China International Capital Corporation up over 4% [7] - Intelligent driving concept stocks surged, with Youjia Innovation up 31.22% [8] Weak Performers - Heavy machinery stocks faced declines, with China National Heavy Duty Truck Group down over 6% [13] - Gold and precious metal stocks were weak, with several companies experiencing declines of over 2% [16] - Oil stocks also fell, with China Petroleum & Chemical Corporation down 1.52% [15] Capital Flows - Southbound funds recorded a net purchase of HKD 3.371 billion, with net selling from Shanghai-Hong Kong Stock Connect and net buying from Shenzhen-Hong Kong Stock Connect [18] Market Outlook - CITIC Securities suggests that after a strong performance in September, Hong Kong stocks are undergoing a mid-term adjustment, with quality assets entering a high-value zone [18]

证券日报网讯 12月18日晚间，君实生物发布公告称，截至本公告披露日，上海檀英投资合伙企业（有 限合伙）（以下简称"上海檀英"）持有上海君实生物医药科技股份有限公司（以下简称"公司"或"君实 生物"）股份59，459，326股，股份性质为A股，占公司总股本的5.7914%。上海檀英长期看好公司的发 展，因基金期限与流动性资金安排原因，计划通过大宗交易的方式减持其持有的公司股份数量不超过 20，533，797股，减持比例不超过公司总股本的2%。上海檀英为在中国证券投资基金业协会备案的私 募基金，已成功申请适用《上市公司创业投资基金股东减持股份的特别规定》和《上海证券交易所上市 公司创业投资基金股东减持股份实施细则》的减持政策：拟通过大宗交易方式减持的，在任意连续60日 内减持股份的总数不超过公司总股本的2%，自本公告披露之日起15个交易日后的三个月内进行。 （编辑 姚尧） ...